NCT00081926已完成4 期
Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 112
- 试验地点
- 1
研究概览
简要总结
This study will evaluate the molecular response to high dose Gleevec in newly diagnosed patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase. This study will evaluate the ability of Gleevec to reduce the amount of abnormal protein that occurs in patients with CML.
Patients who are eligible to participate will be treated for 18 months. This trial will include male or female patients 18 years or older who are newly diagnosed (within 6 months) with CML.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must meet all of the following criteria:
- •Male or Female patients 18 years and older.
- •Patient with a diagnosis of chronic myelogenous leukemia in chronic phase
- •Within 6 months of initial diagnosis.
- •Received any treatment for CML for less than 1 month prior to study entry with the exception of hydroxyurea and/or anagrelide.
排除标准
- •Late chronic phase, accelerated phase or blastic phase
- •Taking any other investigational agents within 28 days of starting the study
- •If sibling donors have been identified and where allogeneic bone marrow transplantation will be the first line treatment.
- •Another primary malignancy /cancer unless it is not considered clinically significant or does not require active intervention.
- •If patients have heart problems or complications
- •Pregnant or breast-feeding females
- •Severe and/or uncontrolled disease such as diabetes, chronic renal disease, etc.
- •Chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).
- •Diagnosis of human immunodeficiency virus (HIV) infection.
- •Received any treatment for CML for longer than 1 month prior to study entry with the exception of hydroxyurea and/or anagrelide.
- •Patient previously received radiotherapy to greater than 25% of the bone marrow.
- •Patient had a major surgery within 4 weeks prior to study entry
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Glivec in Prostate Cancer Patients With Rising PSA Following Radical ProstectomyProstatic NeoplasmGenital Neoplasms, MaleNeoplasms, AbdominalUrogenital NeoplasmsGenital Diseases, MaleProstatic DiseasesAntineoplastic AgentsImatinibNCT01316458Novartis Pharmaceuticals51
已完成
2 期
Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic SyndromesLeukemia, MyeloidMyelodysplastic SyndromesNCT00451997M.D. Anderson Cancer Center10
已完成
2 期
Gleevec and Gemzar in Patients With Epithelial Ovarian CancerPrimary Peritoneal CancerOvarian CancerNCT00928642Henry M. Jackson Foundation for the Advancement of Military Medicine8
进行中（未招募）
1 期
Ph3 trial of Glivec in CML-CP patients previously untreated with IFN-alfaCML-CP patientsEUCTR2017-001804-31-Outside-EU/EEAovartis Pharma K.K107
已完成
1 期
Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHDChronic Versus Graft Host DiseaseNCT02318082Dana-Farber Cancer Institute21